<DOC>
	<DOCNO>NCT02226133</DOCNO>
	<brief_summary>Exclusion LAA ( Left Atrial Appendage ) use TigerPaw II System VATS technique safe effective .</brief_summary>
	<brief_title>Video-Assisted Left Atrial Appendage Exclusion Trial</brief_title>
	<detailed_description>The objective confirmatory study demonstrate LAAx , Inc. TigerPaw® II System safely effectively use exclude Left Atrial Appendage ( LAA ) cardiac surgery utilize thoracoscopic camera light source thus remove , clear indication use , direct vision limitation .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>1 . Greater equal 18 year age ; 2 . Capable willing give inform consent ; 3 . Able willing complete 30 day ± 7 day followup evaluation ; 4 . Ejection fraction ≥ 30 % ; 5 . Life expectancy &gt; 1 year ; 6 . Stroke Risk ( CHADS score ≥ 1 ) , CHADS scoring : CHF=1 point , Hypertension ( treat hypertension ) = 1 point , Age &gt; 75 = 1 point , Diabetes = 1 point , Prior stroke TIA = 2 point ; 7 . Subjects suitable elective VideoAssisted Thoracoscopic Surgical ( VATS ) procedure ( ) include , limited , cardiac surgery one following : 1. mitral valve repair replacement , 2. aortic valve repair replacement , 3. tricuspid valve repair replacement , 4. coronary artery bypass procedure , 5. concomitant surgical ( ablation cut sew ) Maze procedure ablation procedures 6. hybrid procedure include combination surgical interventional procedure surgical procedure combination leave right thoracic access sit 1 . Previous cardiac surgery ; 2 . Active systemic cutaneous infection inflammation ; 3 . Preexisting immunodeficiency disorder and/or chronic use systemic steroid include intermittent use inhale steroid respiratory disease ; 4 . Known , significant history bleed diathesis , coagulopathy , von Willebrand 's disease current platelet count &lt; 100,000 cells/mm3 , baseline INR ≥1.8 , fibrinogen level le 150 mg/dl ( receive fibrinolytic agent within prior 24 hour ) ; 5 . Severe coexist morbidity life expectancy le 1 year ; 6 . Currently involve investigational clinical trial complete primary endpoint may interfere TigerPaw study result ; 7 . Thrombus LAA/LA ; 8 . NYHA Class IV heart failure symptom ; 9 . Mental impairment condition may allow subject understand nature , significance scope study cooperate followup requirement ; 10 . Preoperative need intraaortic balloon pump ; 11 . Significant anemia hemoglobin level le 10 g/dL hematocrit le 30 % ; 12 . Females pregnant , plan become pregnant within 1 month procedure , lactate ; 13 . Extreme morbid obesity ( BMI great 45 kg/m2 ) ; 14 . Any active medical condition would preclude patient completing study would result unreasonable risk ; 15 . Contraindication Transesophageal Echocardiography ( TEE ) ; 16 . Need emergent cardiac surgery ( e.g. , cardiogenic shock ) ; 17 . Creatinine &gt; 200 umol/L ; 18 . Renal failure require dialysis hepatic failure ; 19 . A known drug and/or alcohol addiction ; 20 . Concurrent chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>